

**JAGSONPAL PHARMACEUTICALS LIMITED**

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

JPL/SEC/RESU-NOT

Date: November 10th, 2012

The National Stock Exchange of India Limited
Kind Attn. Mr. Hari K. - Vice President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041

**SUB: UNAUDITED FINANCIAL RESULTS FOR QUARTER
ENDED 30.09.2012 & LIMITED REVIEW**

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith unaudited financial results (provisional), Statement of Assets and Liabilities for the quarter ended 30th September, 2012 and Limited Review.

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**


(S.K. MATA)**COMPLIANCE OFFICER / COMPANY SECRETARY**

Encl. : As above.

Unaudited Financial Results for the Quarter ended 30.09.2012

	Rs. in lacs					
Particulars	3 months ended 30.09.2012 Unaudited	3 months ended 30.06.2012 Unaudited	3 months ended 30.09.2011 Unaudited	6 Months ended 30.09.2012 Unaudited	6 Months ended 30.09.2011 Unaudited	12 Months Ended 31.03.2012 Audited
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	4178.33	3722.69	4765.49	7901.02	8845.53	17651.39
b Other Operating Income						
Total Income from operations (net)	4178.33	3722.69	4765.49	7901.02	8845.53	17651.39
2 Expenses						
a Cost of materials consumed	1437.22	1651.38	2367.77	3088.80	4449.21	7955.91
b Purchases of stock-in-trade	308.25	454.25	290.03	762.50	436.28	1572.28
c Changes in inventories of finished goods, work in progress and Stock in trade	332.82	-361.54	-368.32	-28.72	-551.53	-1073.60
d Employee benefits expenses	963.73	867.06	927.74	1830.79	1778.23	3650.73
e Depreciation and amortisation expense	69.92	85.18	62.15	135.10	120.08	253.58
f Other expenses	866.03	915.52	1061.50	1781.55	1907.20	3884.60
Total expenses	3977.97	3591.85	4340.87	7569.82	8139.47	16243.50
3 Profit from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	200.36	130.84	424.62	331.20	706.06	1407.89
4 Other Income			6.01	0.00	6.01	36.92
5 Profit from ordinary activities before finance cost and Exceptional Items (3+4)	200.36	130.84	430.63	331.20	712.07	1444.81
6 Finance Cost	125.42	115.78	103.62	241.20	179.65	435.82
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	74.94	15.06	327.01	90.00	532.42	1008.99
8 Exceptional Items						
9 Profit/(+)/Loss(-) from Ordinary Activities before tax (7+8)	74.94	15.06	327.01	90.00	532.42	1008.99
10 Tax expense	33.00	15.00	73.00	48.00	113.00	283.31
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	41.94	0.06	254.01	42.00	419.42	745.68
12 Extraordinary Items (net of tax expense Rs. lacs)						
13 Net Profit/(+)/Loss(-) for the period (11-12)	41.94	0.06	254.01	42.00	419.42	745.68
14 Share of profit/(Loss) of associates						
15 Minority interest						
16 Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13-14-15)	41.94	0.06	254.01	42.00	419.42	745.68
17 Paid up Eq. Sh. Cap. (Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr						7208.47
19.i Earnings Per Share (before extraordinary items)						
a. Basic (Rs.)	0.16	0.00	0.97	0.16	1.60	2.85
b. Diluted (Rs.)	0.16	0.00	0.97	0.16	1.60	2.85
19.ii Earnings Per Share (after extraordinary items)						
a. Basic (Rs.)	0.16	0.00	0.97	0.16	1.60	2.85
b. Diluted (Rs.)	0.16	0.00	0.97	0.16	1.60	2.85
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of shares	8962360	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%	34.21%
2 Promoter and promoter group shareholding						
A Pledged / encumbered						
- Number of shares						
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)						
- Percentage of shares (as a % of the total share capital of the Company)						
B Non - encumbered						
- Number of shares	17235640	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%	65.79%
B INVESTOR COMPLAINTS						
Pending at the beginning of the quarter	0					
Received during the quarter	27					
Disposed of during the quarter	27					
Remaining unresolved at the end of the quarter	0					

Notes

- The Unaudited Financial Results for the Quarter ended 30.9.2012 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 10.11.2012
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.

Place : New Delhi
Date : 10.11.2012



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Rajpal Singh Kochhar
Chairman & Managing Director


JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi 110049

Statement of Assets and Liabilities

Rs. In lacs			Rs. In lacs		
A	As at 30.09.2012	As at 30.09.2011	B	As at 30.09.2012	As at 30.09.2011
EQUITY AND LIABILITIES			ASSETS		
1 Shareholders' funds			1 Non-current assets		
(a) Share Capital	1309.90	1309.90	(a) Fixed Assets	5895.43	5856.83
(b) Reserves and surplus	8584.64	8400.91	(b) Goodwill	3.00	3.00
Sub-total - Shareholders' funds	9894.54	9710.81	(c) Non-current investments	0.05	0.05
2 Share application money pending allotment	0.00	0.00	(d) Deferred tax assets (net)	0.00	0.00
3 Minority Interest	0.00	0.00	(e) Long term loans and advance	527.92	482.80
4 Non-current liabilities			(f) Other non-current assets	0.00	0.00
(a) Long term borrowings	26.92	21.81	Sub-total - Non-current assets	6426.40	6342.68
(b) Deferred tax liabilities (net)	428.27	351.77	2 Current assets		
(c) Other long term liabilities	0.00	0.00	(a) Current investments		
(d) Long term provisions	0.00	0.00	(b) Inventories	3674.67	3067.49
Sub-total - Non-current liabilities	455.19	373.58	(c) Trade receivables	4136.64	3632.48
5 Current liabilities			(d) Cash and Cash equivalents	965.87	665.66
(a) Short term borrowing	3547.47	2347.64	(e) Short term loans and advance	342.38	206.74
(b) Trade payables	655.02	567.87	(f) Other current assets	0.00	0.00
(c) Other current liabilities	468.72	436.41	Sub-Total - Current assets	9119.56	7572.37
(d) Short term provisions	525.02	478.74			
Sub-Total - Current liabilities	5196.23	3830.66			
TOTAL - EQUITY AND LIABILITIES	15545.96	13915.05	TOTAL - ASSETS	15545.96	13915.05

For Jagsonpal Pharmaceuticals Limited



Rajpal Singh Kochhar

Rajpal Singh Kochhar
Chairman & Managing Director

Place : New Delhi
Date : 10.11.2012

P.P. THUKRAL & CO.
CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre,
Babar Road, New Delhi - 110 001
Ph. (O) : 23413486
E-mail : sureshsethi62@yahoo.com

Limited review report for Jagsonpal Pharmaceuticals Limited

To whom it may concern

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.09.2012, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO.,
Chartered Accountants

Place : New Delhi
Date : 10.11.2012



Suresh Sethi
SURESH SETHI
PARTNER
F.R. No. 000632 N
Membership no. 89318